WYSZOMIERSKI JACK L 4

4 · EXELIXIS, INC. · Filed Feb 20, 2026

AI-generated summary of this filing

Updated Feb 21, 2026

Exelixis Director Jack Wyszomierski Sells 99,574 Shares, Exercises Options

What Happened

Jack L. Wyszomierski, a director of Exelixis, Inc. (EXEL), reported transactions on Feb 18, 2026. He exercised options to acquire 20,634 shares at $19.77 per share (total outlay $407,934). The filing also shows an open-market sale of 99,574 shares at a weighted average price of $44.01, netting approximately $4,382,252.
The Form 4 also reports a disposition entry for 20,634 derivative securities at $0 (see Key Details). The exercise option became fully exercisable on May 23, 2019.

Key Details

Transaction date: February 18, 2026.
Option exercise: 20,634 shares @ $19.77 = $407,934 (code M).
Open‑market sale: 99,574 shares @ weighted avg $44.01 = $4,382,252 (code S). Reported sale prices ranged from $43.32 to $44.49.
Derivative disposition: 20,634 shares reported disposed at $0 (derivative line) — see the filing for the specific mechanics.
Plan/authorization: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 19, 2025 (footnote F2).
RSUs: Footnote indicates 9,812 RSUs are included in holdings and will be issued upon vesting (F1).
Option background: The option exercised was fully exercisable as of May 23, 2019 (F4).
Shares owned after transaction: Not specified in the excerpt provided; consult the full Form 4 for post-transaction beneficial ownership.
Timeliness: No late filing flag noted in the provided data.

Context

The filing shows both an exercise of long-held options and a substantial open-market sale executed under a pre-established 10b5-1 plan. Exercises followed by sales can be routine (e.g., to cover taxes or diversify); the presence of a 10b5-1 plan indicates the sale schedule was pre-planned.
For a full picture of insider exposure and timing, review the complete Form 4 and any company disclosures (the derivative disposal at $0 may reflect net settlement or an internal transfer — the filing or company can provide specifics).

Form 4

Period: 2026-02-18

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-18$19.77/sh+20,634$407,934→ 379,516 total
Sale
Common Stock
[F2][F3][F1]
2026-02-18$44.01/sh−99,574$4,382,252→ 279,942 total
Exercise/Conversion
Option (right to buy)
[F4]
2026-02-18−20,634→ 0 total
Exercise: $19.77From: 2019-05-23Exp: 2026-05-22→ Common Stock (20,634 underlying)

Footnotes (4)

[F1]Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
[F2]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
[F3]Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $43.32 to $44.49. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
[F4]The option, representing the right to purchase a total of 20,634 shares of Common Stock, became fully exercisable on May 23, 2019.

Signature

/s/ Nina Ayer, Attorney in Fact|2026-02-20

1 file